Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11350MR)

This product GTTS-WQ11350MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11350MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12200MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ14232MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ4402MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ1301MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ7699MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ5462MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ3012MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW